SAN FRANCISCO, Nov. 19, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises ImmunityBio, Inc. investors that the firm is investigating potential legal claims relating to the company's unsuccessful efforts in 2023 to secure regulatory approval for its flagship product Anktiva, designed to treat bladder cancer. Current shareholders are encouraged to contact the firm.On June 20, 2024, Judge Gonzalo P. Curiel of the U.S. District Court for the Southern District of California issued an order denying in p ...